» Articles » PMID: 12752675

Neutrophil Apoptosis Pathways and Their Modifications in Inflammation

Overview
Journal Immunol Rev
Date 2003 May 20
PMID 12752675
Citations 122
Authors
Affiliations
Soon will be listed here.
Abstract

Neutrophils are constantly produced in large numbers in the bone marrow, and the same numbers of cells need to die within a defined time period in order to keep cellular homeostasis under physiologic conditions. Changing the rate of apoptosis rapidly changes cell numbers in such systems. For instance, in many bacterial and autoimmune inflammatory diseases, delayed apoptosis is one important mechanism for neutrophil accumulation. Excessive production of granulocyte/macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF), two important neutrophil survival factors, is often observed in such inflammatory responses. Cytokine withdrawal, as it occurs in the resolution phase of inflammation, leads to the induction of apoptosis. Moreover, neutrophil apoptosis can be accelerated both in the presence and in the absence of survival factors by activation of distinct members of the tumor necrosis factor/nerve growth factor receptor family. This review focuses on recently published work regarding signaling pathways that regulate neutrophil apoptosis.

Citing Articles

Combustion-derived carbon nanoparticles cause delayed apoptosis in neutrophil-like HL-60 cells in vitro and in primed human neutrophilic granulocytes ex vivo.

Hornstein T, Spannbrucker T, Unfried K Part Fibre Toxicol. 2025; 22(1):6.

PMID: 40065392 PMC: 11892137. DOI: 10.1186/s12989-025-00621-0.


Activated neutrophils: A next generation cellular immunotherapy.

Kumbhojkar N, Mitragotri S Bioeng Transl Med. 2025; 10(1):e10704.

PMID: 39801751 PMC: 11711228. DOI: 10.1002/btm2.10704.


The Multifaceted Roles of Neutrophil Death in COPD and Lung Cancer.

Wan A, Chen D J Respir Biol Transl Med. 2025; 2(1).

PMID: 39759427 PMC: 11694489. DOI: 10.70322/jrbtm.2024.10022.


Advances and Challenges in Sepsis Management: Modern Tools and Future Directions.

Santacroce E, DAngerio M, Ciobanu A, Masini L, Lo Tartaro D, Coloretti I Cells. 2024; 13(5.

PMID: 38474403 PMC: 10931424. DOI: 10.3390/cells13050439.


Development and characterization of DIA 12.3, a fully human intact anti-CEACAM1 monoclonal antibody.

Centonze M, Fiori V, Kujawski M, Li L, Wong P, Williams L PLoS One. 2024; 19(2):e0295345.

PMID: 38346003 PMC: 10861082. DOI: 10.1371/journal.pone.0295345.